Stocks · Healthcare · Biotechnology
Avalo Therapeutics, Inc. AVTX
$14.60 -2.60% Close, Oct 5, 2026 · NASDAQ · Market cap $788.0M
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-4.74, down 150.2% year over year.
- Revenue over the last four quarters was $59,000, down 86.6% from a year earlier.
- Operating margin narrowed to -154844.1% from -13641.0% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 6%
- EPS growth (TTM, YoY)Bottom 15%
- Revenue growth, 3-year CAGRBottom 1%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 49%
- Gross marginBottom 1%
- Operating marginBottom 1%
- Accruals (lower is better)Top 48%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 22%
- Free-cash-flow yieldBottom 41%
- EBITDA / enterprise valueBottom 33%
- Sales / enterprise valueBottom 2%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 35%
- 6-month returnBottom 31%
- 1-year return vs S&P 500Bottom 49%
- Distance from 52-week highBottom 39%
- Trend checklist (0–4)Bottom 36%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 33%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 45%
- Upside to consensus price targetTop 19%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 46%
- Maximum drawdown, 3 yearsBottom 14%
- Beta vs S&P 500 (lower is better)Bottom 41%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -86.6% | -86.6% | → |
| EPS growth (YoY) | -124.1% | -150.2% | ↓ |
| Gross margin | -3515.6% | -16861.0% | ↓ |
| Operating margin | -13641.0% | -154844.1% | ↓ |
| FCF margin | -10752.4% | -112505.1% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -86.6% | -86.6% | → | Bottom 6% |
| EPS growth (TTM, YoY) | -150.2% | -124.1% | ↓ | Bottom 15% |
| Gross margin | -16861.0% | -3515.6% | ↓ | Bottom 1% |
| Operating margin | -154844.1% | -13641.0% | ↓ | Bottom 1% |
| Net margin | -170055.9% | -10479.8% | ↓ | — |
| Free-cash-flow margin | -112505.1% | -10752.4% | ↓ | — |
| Return on invested capital | -19.4% | — | Top 49% | |
| Revenue growth, 3-year CAGR | -85.2% | — | Bottom 1% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -6.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 28037.3%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -56.66%
- Shareholder yield
- -56.66%
- Share count change, 1 year
- +302.6%
- Share count change, 3-year CAGR
- +808.1%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -4.9%
- Average 2-day reaction, last 8
- -0.9%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $45.13
- Target vs current price
- +209.1%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 80%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -42.4% | -0.7% | +3.8% | +2.7% | — |
| May 13, 2026 | +2.0% | -0.5% | -18.4% | -34.3% | -8.1% |
| Mar 23, 2026 | +51.9% | +0.6% | +3.5% | +9.2% | +6.8% |
| Nov 6, 2025 | -31.1% | -6.3% | -6.2% | +9.1% | -3.0% |
| Aug 7, 2025 | -34.3% | +0.5% | +9.1% | +22.3% | +117.1% |
| May 12, 2025 | -16.8% | -1.5% | -3.7% | +12.3% | +104.7% |
| Mar 27, 2025 | -78.3% | +4.4% | -15.3% | -41.6% | -42.7% |
| Nov 7, 2024 | -137.8% | -3.7% | +0.0% | -25.5% | -37.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.83 | -$0.58 | -42.4% | — |
| May 13, 2026 | -$0.98 | -$1.00 | +2.0% | — |
| Mar 23, 2026 | -$0.74 | -$1.54 | +51.9% | $79,500 |
| Nov 6, 2025 | -$2.19 | -$1.67 | -31.1% | — |
| Aug 7, 2025 | -$1.92 | -$1.43 | -34.3% | — |
| May 12, 2025 | -$1.25 | -$1.07 | -16.8% | — |
| Mar 27, 2025 | -$2.30 | -$1.29 | -78.3% | $200,000 |
| Nov 7, 2024 | -$2.83 | -$1.19 | -137.8% | $249,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 11912.18× | — | — | Bottom 2% |
| Free-cash-flow yield | -8.42% | — | — | Bottom 41% |
| Earnings yield | -32.47% | — | — | Bottom 22% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.4%
- 200-day average slope (20 days)
- -1.2%
- Distance from 50-day average
- -19.3%
- Distance from 200-day average
- -12.6%
- RSI (14)
- 32.3
- Relative volume
- 0.62×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 54.1%
- Volatility vs own 5-year history
- 4th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.27
- Correlation with S&P 500
- 0.20
- Current drawdown from 1-year high
- -36.2%
- Maximum drawdown, 3 years
- -90.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 19, 2021 | May 28, 2025 | -100.0% | 1072 days | Not yet recovered |
| Oct 12, 2020 | Nov 2, 2020 | -18.6% | 15 days | 18 days (Nov 27, 2020) |
| Jan 5, 2021 | Jan 11, 2021 | -15.1% | 4 days | 6 days (Jan 20, 2021) |
| Jan 22, 2021 | Jan 27, 2021 | -13.4% | 3 days | 8 days (Feb 8, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $788.0M
- EPS, diluted (TTM)
- -$4.74
- Revenue (TTM)
- $59,000
- 52-week range
- $12.51 – $24.27
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $5.4M | $18.1M | $1.9M | $441,000 | $59,000 |
| Gross profit | $3.9M | $14.6M | $640,000 | $807,000 | $59,000 |
| Operating income | -$82.1M | -$37.4M | -$27.4M | -$68.5M | -$72.9M |
| Net income | -$84.4M | -$41.7M | -$31.5M | -$35.1M | -$78.3M |
| EPS (diluted) | -$2,330.66 | -$1,062.65 | -$113.58 | -$3.26 | -$5.84 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $249,000 | $192,000 | $0 | $0 | $0 | $59,000 | $0 | $0 |
| Net income | $23.0M | -$35.3M | -$13.1M | -$20.8M | -$30.6M | -$13.7M | -$19.6M | -$36.4M |
| EPS (diluted) | $2.14 | $10.47 | -$1.25 | -$1.92 | -$2.19 | -$0.74 | -$0.98 | -$0.83 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$70.9M | -$26.8M | -$30.7M | -$49.1M | -$51.5M |
| Capital expenditure | -$113,000 | -$95,000 | -$158,000 | $0 | $0 |
| Free cash flow | -$71.0M | -$26.8M | -$30.8M | -$49.1M | -$51.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $71.9M | $107,000 | $46.2M | $115.6M | $15.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $400.3M
- Total assets
- $490.8M
- Total liabilities
- $42.1M
- Total debt
- $242,000
- Net debt
- -$85.1M
- Shareholders’ equity
- $448.7M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 12,925,869
- Days to cover
- 13.24
- Change vs previous report
- +4.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Dec 29, 2023
- 1-for-240
- Jul 8, 2022
- 1-for-12